Technology ID
TAB-5039
Stable Cell Line Technology for Enhanced Production of Varicella-Zoster Virus Vaccines
E-Numbers
E-491-2013-0
Lead Inventor
Cohen, Jeffrey (NIAID)
Co-Inventors
Liu, Xueqiao (NIAID)
Development Stages
Pre-Clinical (in vitro)
ICs
NIAID
This technology includes a stable cell line engineered to have reduced expression of the pro-apoptotic protein Bim when exposed to doxycycline. This reduction in Bim expression allows for significantly higher yields of the Varicella-Zoster Virus (VZV), which is used in the production of live, attenuated VZV vaccines. The enhanced viral production makes this cell line particularly useful for vaccine manufacturing.
Commercial Applications
This technology can be applied in the production of childhood vaccines against VZV, such as those for chickenpox and shingles. It also has potential research applications for studying apoptosis and viral replication mechanisms.
Competitive Advantages
This cell line technology provides a tenfold increase in VZV production, which can significantly reduce production costs for VZV vaccines. Additionally, it offers a more efficient method for growing high-titer vaccine strains compared to standard cell lines.
Licensing Contact: